This case series and propensity-matched cohort study on the use of tigecycline in Clostridioides difficile infection (CDI) evaluated the effect of tigecycline on 30-day mortality. Adjusted for ATLAS Score, hypotension, treatment time period, and serum lactate, tigecycline did not significantly improve 30-day mortality (odds ratio: 0.89; 95% confidence interval: 0.25-3.12; 0.853). A randomized controlled trial is needed to determine efficacy and safety of tigecycline in severe or refractory CDI.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9211400 | PMC |
| http://dx.doi.org/10.1128/aac.00001-22 | DOI Listing |
Publication Analysis
Top Keywords
case series
8
series propensity-matched
8
30-day mortality
8
impact tigecycline
4
tigecycline difficile
4
difficile outcomes
4
outcomes case
4
propensity-matched retrospective
4
retrospective study
4
study case
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!